Sign Out
Zemiglo 50 mg is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Zemiglo 50 mg can be administered as monotherapy or in combination with metformin as initial therapy in treatment naïve patients with inadequate glycemic control by diet and exercise; metformin in patients with inadequate glycemic control with maximal tolerated dose of metformin alone; metformin and sulfonylurea in patients with inadequate glycemic control with the maximal tolerated dose of metformin and sulfonylurea dual therapy; insulin (with or without metformin) in patients with inadequate glycemic control with insulin alone or insulin and metformin dual therapy; dapagliflozin and metformin in patients with inadequate glycemic control with dapagliflozin and metformin dual therapy.
Continue with Google